Tenet Healthcare (NYSE:THC) Issues Earnings Results, Beats Estimates By $1.86 EPS

Tenet Healthcare (NYSE:THC) issued its quarterly earnings data on Thursday. The company reported $6.12 EPS for the quarter, beating the consensus estimate of $4.26 by $1.86, FiscalAI reports. The business had revenue of $5.63 billion during the quarter, compared to the consensus estimate of $5.43 billion. Tenet Healthcare had a net margin of 7.94% and a return on equity of 25.55%. Tenet Healthcare updated its FY 2026 guidance to 20.300-21.690 EPS.

Tenet Healthcare Trading Up 2.3%

Shares of NYSE:THC traded up $4.50 during midday trading on Thursday, reaching $199.85. The company’s stock had a trading volume of 1,728,933 shares, compared to its average volume of 1,246,234. The firm has a 50 day moving average price of $184.41 and a two-hundred day moving average price of $197.37. Tenet Healthcare has a fifty-two week low of $146.60 and a fifty-two week high of $247.21. The firm has a market capitalization of $17.22 billion, a price-to-earnings ratio of 10.39, a PEG ratio of 1.63 and a beta of 1.27. The company has a debt-to-equity ratio of 1.96, a quick ratio of 1.30 and a current ratio of 1.36.

Insiders Place Their Bets

In related news, Director Nadja West sold 3,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $177.35, for a total transaction of $532,050.00. Following the transaction, the director directly owned 24,805 shares of the company’s stock, valued at approximately $4,399,166.75. This represents a 10.79% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director J Robert Kerrey sold 5,638 shares of the business’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $174.52, for a total transaction of $983,943.76. Following the sale, the director owned 16,804 shares of the company’s stock, valued at $2,932,634.08. This trade represents a 25.12% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 0.97% of the company’s stock.

Hedge Funds Weigh In On Tenet Healthcare

Hedge funds have recently bought and sold shares of the company. Wellington Management Group LLP lifted its position in shares of Tenet Healthcare by 1,114.2% during the 4th quarter. Wellington Management Group LLP now owns 1,135,801 shares of the company’s stock valued at $225,706,000 after buying an additional 1,042,260 shares during the last quarter. Boston Partners raised its stake in Tenet Healthcare by 38.8% in the 3rd quarter. Boston Partners now owns 3,147,555 shares of the company’s stock valued at $638,958,000 after acquiring an additional 880,413 shares during the period. AQR Capital Management LLC boosted its position in Tenet Healthcare by 62.3% during the third quarter. AQR Capital Management LLC now owns 1,876,423 shares of the company’s stock worth $380,989,000 after purchasing an additional 720,160 shares during the period. Alliancebernstein L.P. increased its stake in shares of Tenet Healthcare by 375.7% in the second quarter. Alliancebernstein L.P. now owns 790,254 shares of the company’s stock worth $139,085,000 after purchasing an additional 624,125 shares in the last quarter. Finally, 8 Knots Management LLC bought a new stake in shares of Tenet Healthcare in the second quarter valued at approximately $48,498,000. 95.44% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on THC. TD Cowen reduced their price objective on Tenet Healthcare from $242.00 to $233.00 and set a “buy” rating on the stock in a research report on Monday, June 22nd. Royal Bank Of Canada cut their price target on Tenet Healthcare from $277.00 to $236.00 and set an “outperform” rating on the stock in a research note on Friday, May 1st. Weiss Ratings downgraded Tenet Healthcare from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Tuesday, June 2nd. Robert W. Baird reduced their target price on shares of Tenet Healthcare from $245.00 to $210.00 and set a “neutral” rating on the stock in a report on Tuesday, May 5th. Finally, Wall Street Zen downgraded shares of Tenet Healthcare from a “buy” rating to a “hold” rating in a research note on Saturday, July 18th. Seventeen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $244.84.

About Tenet Healthcare

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.